CBLL Stock — CeriBell, Inc

CeriBell, Inc (CBLL)

Updated October 16, 2026.

CBLL is a Stock. Total return is 47.3% over the past 2 years, 11.8 points ahead of SPY at 35.5%.

CeriBell, Inc. is a medical technology company that develops the Ceribell System, a point-of-care EEG platform for acute care settings, along with associated disposable headbands and headcaps, a portable EEG recorder, an AI-powered seizure detection algorithm, and a remote EEG data portal. The company does not currently have an established distribution pattern. This security may appeal to investors seeking exposure to healthcare innovation and medical device development.

CBLL performance versus SPY

Price and return data through 2026-10-16.

Total return is 47.3% over the past 2 years, 11.8 points ahead of SPY at 35.5%. Over the past year its total return — price change plus distributions reinvested — is 92.8%. Its deepest 1-year drawdown was 30.5%.

CBLL key facts

Asset type

Stock

Asset class

Equity

Inception date

10/10/2024

Distribution frequency

None

Last close

$25.04 (as of 2026-10-16)

Market cap

$960,987,649

Average volume

406586.0

Beta

0.931

Payout ratio

0.0%

EPS

$-1.76

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CBLL risks and drawbacks

The deepest 1-year drawdown on record here is 30.5%.

Who may consider CBLL — and who may not

It is a weaker fit for investors who need monthly cash flow (CBLL does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on CBLL

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions